Amferia
Daniel Hagberg has a diverse work experience in various roles and industries. Daniel is currently working as the CTO at Amferia since April 2022. Prior to that, they were a Product Manager at Amferia from September 2021 to April 2022.
Before joining Amferia, Daniel worked at Essity as a Material Development Manager from June 2017 to September 2021. Daniel also held the same role at SCA - Hygiene and Forest Products Company from April 2014 to June 2017.
Daniel's earlier experience includes working at AkzoNobel as a Research Chemist from May 2010 to April 2014. During their time at AkzoNobel, they also served as a Global Project Manager from November 2011 to December 2012.
Apart from their industry experience, Daniel has served as a Board Member at Road2Science / KTH from May 2012 to March 2014. Daniel completed their Ph.D. at KTH, starting in April 2005 and finishing in August 2009.
Daniel Hagberg earned their Bachelor of Science degree in Chemistry from Chalmers University of Technology, where they studied from 1999 to 2005. Following this, they pursued a Ph.D. in Organic Chemistry at KTH Royal Institute of Technology, completing their studies from 2005 to 2009.
This person is not in any teams
Amferia
Amferia develops innovative medical devices to provide solutions to the global antibiotic resistance crisis. Amferia’s core focus is preventive healthcare where the goal is to provide highly efficient anti-infective medical devices that can prevent bacterial infections including those caused by antibiotic resistant bacteria. Our dominant focus iswithin the wound care sector, producing preventive care wound patches for the pressing need to avoid antibiotic resistant skin infections. Amferia’s proprietary anti-infective technology is a result of several years of research from Chalmers University of Technology and is patent protected.